SGMOQ SANGAMO THERAPEUTICS, INC
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1001233 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-31.6%
TTM net income YoY-25.5%
TTM EPS YoY10.2%
Revenue 3-yr CAGR-29.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-306.5%
Net margin-310.8%
FCF margin-246.0%
EBITDA margin-296.5%
Returns
ROE-2,891.8%
ROA-152.4%
ROIC (approx.)—
Asset turnover0.49x
Leverage & solvency
Liabilities / assets123.9%
Debt / equity—
Current ratio0.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-31.9%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.44M | $14.23M | $581,000 | $18.31M | $6.44M | $7.55M | $49.41M | $356,000 |
| R&D expense | $26.57M | $31.44M | $28.14M | $27.08M | $26.01M | $23.68M | $27.73M | $24.22M |
| SG&A expense | $6.82M | $7.76M | $7.99M | $9.08M | $10.06M | $9.87M | $11.05M | $12.04M |
| Operating income | -$31.95M | -$38.20M | -$35.55M | -$17.86M | -$29.63M | -$25.99M | $10.63M | -$37.08M |
| Pretax income | -$31.00M | -$37.97M | -$35.09M | -$19.96M | -$30.48M | -$23.82M | $10.76M | -$36.05M |
| Income tax | $0 | -$553,000 | -$161,000 | $27,000 | $119,000 | -$427,000 | $88,000 | $74,000 |
| Net income | -$31.00M | -$37.42M | -$34.93M | -$19.99M | -$30.60M | -$23.40M | $10.67M | -$36.13M |
| EBITDA | -$31.23M | -$37.24M | -$34.56M | -$16.86M | -$28.61M | -$24.75M | $11.85M | -$35.84M |
| EPS (basic) | -0.08 | — | -0.11 | -0.08 | -0.14 | — | 0.05 | -0.18 |
| EPS (diluted) | -0.08 | — | -0.11 | -0.08 | -0.14 | — | 0.04 | -0.18 |
| Weighted avg. shares (diluted) | 389.62M | — | 304.27M | 256.95M | 220.27M | — | 214.32M | 203.95M |
| Balance sheet | ||||||||
| Cash & equivalents | $27.59M | $20.95M | $29.62M | $38.34M | $25.18M | $41.92M | $39.20M | $27.79M |
| Receivables | $873,000 | $371,000 | $523,000 | $372,000 | $366,000 | $526,000 | $10.50M | $581,000 |
| Current assets | $37.11M | $35.83M | $44.08M | $49.89M | $37.60M | $51.69M | $58.13M | $40.08M |
| PP&E, net | $10.32M | $11.04M | $14.79M | $15.73M | $16.88M | $17.89M | $19.15M | $20.62M |
| Goodwill | — | — | — | — | — | $0 | — | — |
| Intangibles | — | — | — | — | — | $0 | — | — |
| Total assets | $59.97M | $59.74M | $88.64M | $97.56M | $86.17M | $101.64M | $111.26M | $93.01M |
| Current liabilities | $53.13M | $42.47M | $50.12M | $47.66M | $49.56M | $45.80M | $43.16M | $39.01M |
| Total liabilities | $78.92M | $74.01M | $82.40M | $77.96M | $81.26M | $78.86M | $72.13M | $69.32M |
| Shareholders' equity | -$18.95M | -$14.27M | $6.24M | $19.60M | $4.91M | $22.77M | $39.13M | $23.69M |
| Shares outstanding | — | 350.69M | — | — | — | 212.84M | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$19.28M | -$24.40M | -$28.50M | -$18.16M | -$26.15M | -$3.35M | $11.76M | -$26.88M |
| Capital expenditure | $13,000 | $14,000 | $64,000 | $24,000 | $0 | $152,000 | $115,000 | $0 |
| Free cash flow | -$19.30M | -$24.42M | -$28.56M | -$18.18M | -$26.15M | -$3.50M | $11.64M | -$26.88M |
| Investing cash flow | -$13,000 | -$14,000 | -$64,000 | -$24,000 | $0 | $1.32M | $233,000 | $127,000 |
| Financing cash flow | $26.70M | $14.80M | $19.20M | $28.61M | $8.13M | $6.99M | -$203,000 | -$533,000 |
| Depreciation & amortization | $719,000 | $959,000 | $989,000 | $993,000 | $1.02M | $1.24M | $1.22M | $1.24M |
| Stock-based compensation | $992,000 | $2.13M | $2.13M | $2.23M | $2.60M | $3.28M | $3.31M | $3.06M |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.